



Mission SECU Cancer Center

PUBLIC REPORTING OF OUTCOMES

August 23, 2019 | Mission Health | 509 Biltmore Avenue

Breast CP3R	Description	CoC Goal	Performance Rate
MASTRT	Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes <i>(Standard 4.4)</i>	90%	100%
BSCRT	Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer. <i>(Standard 4.4) Accountability</i>	90%	91%
HT	Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer. <i>(Standard 4.4) Accountability</i>	90%	97.7%
nBx	Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer <i>(Standard 4.5) Quality Improvement</i>	80%	97%
MAC	Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or stage II or III hormone receptor negative breast cancer. <i>(Standard 4.4) Accountability</i>	N/A	96.2%

CP3R Metrics

% Concordant: Mission SECU Cancer Program, Asheville, NC